Physician profile
John C Gross
NPI 1245209550
$7,434.66
in general payments reported to CMS, 2019-2025
25 companies · $843 in 2025
The $843 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,827 · 2020: $272 · 2021: $588 · 2022: $629 · 2023: $799 · 2024: $477 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,914.85 | 2019-2025 | Clareon, Argos, Unity |
| Microsurgical Technology, INC. | $2,800.00 | 2019 | |
| Abbvie INC. | $291.19 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $213.22 | 2024-2025 | |
| Omeros Corporation | $141.88 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $136.47 | 2022-2025 | Omidria, Rayone Aspheric, Rayone Spheric |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $131.69 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $98.16 | 2019 | |
| Sight Sciences, INC. | $92.22 | 2023-2024 | Omni Surgical System |
| Ocular Therapeutix, INC. | $81.34 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $77.26 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $70.90 | 2021-2025 | Tecnis Simplicity, Tecnis Iol |
| Oyster Point Pharma, INC. | $55.48 | 2022-2025 | Tyrvaya, Ryzumvi |
| Shire North American Group INC | $53.91 | 2019 | |
| Kala Pharmaceuticals, INC. | $37.67 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $35.26 | 2023-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Novartis Pharmaceuticals Corporation | $35.04 | 2021-2023 | |
| Ani Pharmaceuticals, INC. | $31.42 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $24.26 | 2022 | |
| Rxsight INC | $21.64 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Mallinckrodt Hospital Products INC. | $20.86 | 2023 | Acthar |
| Tarsus Pharmaceuticals, INC. | $18.32 | 2025 | Xdemvy |
| Allergan, INC. | $18.08 | 2021 | |
| Thea Pharma INC. | $17.84 | 2025 | Iyuzeh |
| Vyera Pharmaceuticals, LLC | $15.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.